- Moderna's stock surged 500% driven by positive Phase 3 trial data for its personalized cancer vaccine intismeran autogene ...

Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results ...

Explore the potential of a personalized mRNA vaccine that targets specific cancer mutations for advanced melanoma treatment.

The recent success of a late-stage mRNA cancer vaccine, showing the drug stopped the return of melanoma, has boosted hopes ...

Developing a vaccine: UNC’s Lineberger Cancer Center has received a $40 million grant to support vaccine development using AI ...

Laura Ferris urges risk-based melanoma screening and highlights earlier immunotherapy, selective imaging, vaccine limits and ...

A new review published in Genes & Diseases highlights the expanding potential of DNA-based vaccines as a flexible platform ...

The medical core is more specific than a general promise of better cancer care. Moderna and Merck reported on August 19 that ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

The National Institutes of Health plans to launch a public-private partnership in December to speed development of personalized cancer vaccines, according ...

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of cancer immunotherapies, is pressing ahead with plans ...

Iowa’s vaccine policy is up for debate in the hotly contested governor’s race, with the two candidates on the ballot ...